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Normal Dermal Ferrochelatase Activity Does Not Protect Human
Skin from Protoporphyrin-Induced Photosensitivity
To the Editor:
In the January issue of the Journal, Pawliuk et al (2005) report
that normal mice transplanted with bone marrow from a
mouse model of erythropoietic protoporphyria (EPP), BALB/
C-Fechm1Pas, have serum and erythrocyte protoporphyrin
concentrations that are as high as those in the photosensi-
tive donors and yet show only minimal photosensitivity and,
unlike the donors, do not develop liver damage. Further-
more, skin grafts from normal mice were not photosensitive
when implanted onto the backs of protoporphyric mice.
From these fascinating experiments, the authors
conclude that ‘‘in the presence of normal cellular levels of
hepatic and dermal ferrochelatase (FECH), elevated plasma
protoporphyrin levels alone are insufficient to generate
EPP-associated liver disease and significant photosensitiv-
ity’’ and suggest that their findings may provide new strat-
egies for treatment of EPP.
Can these observations be extended to humans? Clinical
observations suggest not. In their discussion, the authors
consider one argument against their hypothesis, namely the
occasional recurrence of disease in the donor liver after
transplantation for protoporphyric liver failure. But they, and
the accompanying Editorial (Lim, 2005), overlook another
clinical observation that is perhaps more pertinent to their
experiments.
The onset of EPP after the age of 40 y is very rare. When
it does occur, it is usually associated with myelodysplastic
syndrome (MDS) or a related disorder (Lim et al, 1992).
Recent molecular investigation of such cases has shown that
they develop EPP as a direct consequence of expansion in
their bone marrows of a clone of hemopoietic cells in which
deletion of one FECH allele leads to massive overproduction of
protoporphyrin (Aplin et al, 2001; Goodwin et al, 2002). For all
other tissues, evidence from analysis of germline DNA (Aplin
et al, 2001; Goodwin et al, 2002), and the observation that EPP
disappears after bone marrow transplantation (Lim et al, 1992),
suggests that FECH activity is likely to be normal, as would be
expected given the hematopoietic stem cell origin of MDS.
This experiment of nature in humans closely parallels
those described in mice by Pawliuk et al (2005). Yet, in spite
of their presumed normal dermal and hepatic FECH activ-
ities, these patients have severe skin photosensitivity (Lim
et al, 1992; Aplin et al, 2001), and one recently reported
case also developed acute protoporphyrin-induced liver
damage (Goodwin et al, 2002). Thus, in humans, an elevat-
ed plasma protoporphyrin concentration does seem to be
all that is required to produce severe skin photosensitivity.
Restoration of dermal FECH activities to normal may there-
fore have less promise as a treatment for EPP than the in-
triguing experiments of Pawliuk et al (2005) would suggest.
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Skin Ferrochelatase Levels and Photosensitivity
Philippe Leboulche and Micheline Mathews-Roth
Harvard University, Boston, Massachusetts, USA
Can the seemingly intuitive clinical counter-examples
provided by Elder rule out the possibility that restoring or
enhancing ferrochelatase activity in the skin of human
patients with the congenital erythropoietic protopor-
phyria (EPP) may prevent skin photosensitivity? We think
not.
Abbreviation: EPP, erythropoietic protoporphyria
Abbreviation: EPP, erythropoietic protoporphyria
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